Akorn, Inc. (AKRX) Misses Q2 EPS by 1c, Comments on Q3 Revenues
More News related to AKRX
- Akorn-Strides, LLC Announces FDA Approvals for Dexamethasone Sodium Phosphate Injection USP, 4 mg (base)/mL and Dexamethasone Sodium Phosphate Injection USP, 10 mg (base)/mL
- Akorn, Inc. to Present at the 2008 UBS Global Life Sciences Conference
- Akorn, Inc. (AKRX) Reports Mixed Q2 Results
- Akorn Reports Second Quarter 2008 Financial Results
- Akorn, Inc. Announces Second Quarter 2008 Earnings Release and Conference Call Information
Akorn, Inc. (NASDAQ: AKRX) reports a Q2 loss of $0.05, 1 cent worse than estimates. Revenues were $11.6 million vs. $13.25 million consensus.
In the third quarter 2007, our expectation is to increase quarterly revenues by at least 50% as compared to the current quarter. This is based on the re-launch of IC-Green(TM), which requires us to successfully pass a pre-approval inspection at our Decatur manufacturing facility, the commercial launch of Tetanus Diphtheria Vaccine, and the launch of our Advanced Vision Research contract manufacturing agreement for TheraTears®." (Q3 revenue consensus is $23.4 million)
Related Categories
EarningsGuidance
Stocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
